Prospective Assessment of Otologic Adverse Events due to Teprotumumab: Preliminary Results. Kay-Rivest E, Belinsky I, Kozlova A, Byrd E, et al. Otolaryngol Head Neck Surg 2023;168:1164-1169.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kay-Rivest E, Belinsky I, Kozlova A, Byrd E, et al. Prospective Assessment of Otologic Adverse Events due to Teprotumumab: Preliminary Results. Otolaryngol Head Neck Surg 2023;168:1164-1169.
PMID: 36939482